Calls on GSK attractive ahead of Advair generic decision – #SaxoStrats
marketwatch May 3, 2017 stakepool.com
GlaxoSmithKline is the most attractive European healthcare stock in our quant model on equities. But in the short term there is risk of FDA approval of a generic replacement for GSK’s Advair drug around May 10. Because of this tail risk we are playing GSK by buying call options.
Who is online right now? Come and chat!
Established in 2014, Stakepool has become the logical community of Bitcoin (very) early adaptors who monitor charts and communities in all branches of Bitcoin, Altcoins, Fintech & even Legacy-markets like the large indexes, forex, commodities and IPO/ICOs. We pride ourself by being the no-bullshit trading community and our users span from all parts of finance & technocracy. For connection instructions to our Discord, click the Discord-tab in the menu.